Fig. 4. (A ) Effects of interleukin (IL)-1β (20 ng/ml) or IL-1β (20 ng/ml) plus halothane (HAL; 3%) exposure on the tis- sue cyclic guanosine monophosphate (cGMP) contents. *P < 0.01 versus  control; #P < 0.01 versus  IL-1β; n = 6 strips each. (B ) Effects of halothane (3%) exposure on the cGMP contents during the exposure period (1, 3, and 5 h; n = 6 strips each). (C ) Effects of IL-1β (20 ng/ml), HAL (3%), or IL-1β (20 ng/ml) plus HAL (3%) exposure on the tissue cyclic adenosine monophosphate (cAMP) contents during the exposure period (1, 3, and 5 h; n = 6 strips each). #P < 0.05 versus  control 5 h.

Fig. 4. (A ) Effects of interleukin (IL)-1β (20 ng/ml) or IL-1β (20 ng/ml) plus halothane (HAL; 3%) exposure on the tis- sue cyclic guanosine monophosphate (cGMP) contents. *P < 0.01 versus  control; #P < 0.01 versus  IL-1β; n = 6 strips each. (B ) Effects of halothane (3%) exposure on the cGMP contents during the exposure period (1, 3, and 5 h; n = 6 strips each). (C ) Effects of IL-1β (20 ng/ml), HAL (3%), or IL-1β (20 ng/ml) plus HAL (3%) exposure on the tissue cyclic adenosine monophosphate (cAMP) contents during the exposure period (1, 3, and 5 h; n = 6 strips each). #P < 0.05 versus  control 5 h.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal